Cabaletta Bio, a biotech startup headquartered in Philadelphia, is making waves with their cutting-edge work on engineered T cell therapies to treat B cell-mediated autoimmune diseases. Currently, the company's lead candidate product, DSG3-CAART, is in Phase I of a clinical trial aimed at treating mucosal pemphigus vulgaris, an autoimmune condition causing blistering skin disease. But that's not all: the pipeline of candidate products includes a preclinical treatment for myasthenia gravis, an investigational therapy called CABA-201, a discovery stage product for PLA2R-associated membranous nephropathy, and a discovery stage product for mucocutaneous pemphigus vulgaris. Cabaletta Bio is also collaborating with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was previously known as Tycho Therapeutics, Inc., but rebranded as Cabaletta Bio, Inc. in 2018. Despite being a relatively new company, Cabaletta Bio is making great strides in their mission to revolutionize autoimmune disease treatment.
Cabaletta Bio, Inc.'s ticker is CABA
The company's shares trade on the NASDAQ stock exchange
They are based in Philadelphia, Pennsylvania
There are 51-200 employees working at Cabaletta Bio, Inc.
It is https://cabalettabio.com/
Cabaletta Bio, Inc. is in the Healthcare sector
Cabaletta Bio, Inc. is in the Biotechnology industry
The following five companies are Cabaletta Bio, Inc.'s industry peers: